About Recombinetics
Recombinetics is a Healthcare company based in Eagan (United States) founded in 2008. Gene-editing technologies are developed for livestock breeding and disease models. It operates in the Healthcare and Agriculture sectors. Recombinetics has raised $65.54 million across 23 funding rounds from investors including NIH, HHS and National Cancer Institute. The company has 29 employees. Recombinetics offers products and services including Gene Edited Swine Models and Precision Breeding Services. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Recombinetics was founded in 2008 and is headquartered in Eagan, United States. Operations focus on the biotechnology sector, where proprietary gene repair and editing tools, including TALEN technologies, are applied. In agriculture, these are used to introduce natural traits into pigs and other livestock, aiming to improve health, welfare, and food safety. In biomedicine, large animal models for human disease research are created to support therapeutic and device development.
- Headquarters Eagan, United States
- Employees 29
- SectorsHealthcareAgriculture
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website recombinetics.com
- Social LinkedIn X Facebook
- Total Equity Funding$65.54M (USD)
in 23 rounds
- Latest Funding Round$385K (USD), Grant
Jun 2024
- InvestorsNIH
& 2 more
- Employee Count29
Products & Services of Recombinetics
Recombinetics offers a comprehensive portfolio of products and services, including Gene Edited Swine Models and Precision Breeding Services.
Custom models for preclinical research to advance healthcare innovations.
Breeding methods to improve animal health and sustainable farming practices.
Funding Insights of Recombinetics
Recombinetics has successfully raised a total of $65.54M across 23 strategic funding rounds. The most recent funding activity was a Grant round of $385 thousand completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65.54M
- Total Rounds 23
- Last Round Grant — $384,999
- First Round $318,202
(May 2011)
- Investors Count 3
Latest 10 of 23 funding rounds of Recombinetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2024 | $384,999 | Grant | – | – | |
| Jun 2023 | $342,154 | Grant | – | – | |
| Jul 2019 | Grant | – | – | ||
| Jun 2019 | $1.22M | Grant | – | – | |
| Aug 2018 | $34M | Series A | – | – | – |
| Jun 2018 | $499,700 | Grant | – | – | |
| Mar 2018 | $6.36M | Series A | – | – | – |
| Jun 2017 | $398,696 | Grant | – | – | |
| Apr 2017 | $6.98M | Series A | – | – | – |
| Nov 2016 | $11M | Series A | – | – | – |
3 investors in total: 3 institutional.
Investors in Recombinetics
Recombinetics has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Recombinetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Recombinetics
18 people are tracked at Recombinetics (7 in leadership, 7 in board & advisors, 4 in team); the tracked headcount is 29.
| Name | Role | Group |
|---|---|---|
Jarryd Campbell | Head of Platform Development | Leadership |
Rocco Morelli | Chief Executive Officer | Leadership |
John Burtis | VP, Legal | Leadership |
William Weimer | Chief IP Counsel | Leadership |
Justin Zenanko | Chief Financial Officer | Leadership |
Matt Tector | Chief Scientific Officer, Makana | Leadership |
Adrienne Watson | VP, Research & Development | Leadership |
Bill Farrell | Board Member | Board & advisors |
Corey Zarecki | Board Member | Board & advisors |
David A. Largaespada | Board Member | Board & advisors |
Tim Clarkson | Board Member | Board & advisors |
Joe Tector | Founder, Makana | Board & advisors |
Scott Rathgaber | Board Member | Board & advisors |
Marylinn Munson | Board Member | Board & advisors |
Sabreena Larson | R&D Project Manager | Team |
Derek Korpela DVM, PhD | Research Scientist Recombinetics | Team |
Alexander Coutts | Research associate and Manger of animal research | Team |
Dan Carlson | SVP, Research & Development | Team |
Complete people profiles for Recombinetics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Recombinetics
3 dated milestones of Recombinetics across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Recombinetics is founded.
- Funding First funding round of $318K.
- Funding Latest funding round, Grant, of $385K.
Competitors of Recombinetics
Recombinetics has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of Recombinetics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Recombinetics
The website of Recombinetics (recombinetics.com) receives about 2.4K visits a month and ranks #8,168,921 among all websites worldwide, #7,276 in Biotechnology and Pharmaceuticals.
- Monthly visits2.4K
▲ 19.6% vs previous month
- Global rank#8,168,921
among all websites
- Category rank#7,276
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.6
- Average visit25 sec
- DevicesDesktop 25% · Mobile 75%
Websites whose visitors overlap most with Recombinetics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biocentury.com | 100% | 85.7K | #514,907 | View details | |
| protalix.com | 87% | 6.5K | #3,462,636 | View details | |
| elan.com | 87% | View details | |||
| vista-technology.com | 87% | View details | |||
| bti-biotechnologyinstitute.com | 54% | 13.3K | #2,299,106 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Recombinetics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Recombinetics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Recombinetics
Complete news archive for Recombinetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Recombinetics
Recombinetics was founded in 2008 and raised its 1st funding round 3 years after it was founded.
Recombinetics is headquartered in Eagan, United States. It is registered at Eagan, Minnesota, United States.
Recombinetics is a funded company, having raised a total of $65.54M across 23 funding rounds to date. The company's 1st funding round was a Series A of $11M, raised on May 2011.
Recombinetics has 29 employees.
Recombinetics was founded in 2008 and is headquartered in Eagan, United States. Operations focus on the biotechnology sector, where proprietary gene repair and editing tools, including TALEN technologies, are applied. In agriculture, these are used to introduce natural traits into pigs and other livestock, aiming to improve health, welfare, and food safety. In biomedicine, large animal models for human disease research are created to support therapeutic and device development.
Recombinetics's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.
Recombinetics offers Gene Edited Swine Models and Precision Breeding Services.
Recombinetics has 3 investors. Key investors include NIH, HHS, and National Cancer Institute.